See more : Hempfusion Wellness Inc. (CBDHF) Income Statement Analysis – Financial Results
Complete financial analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reviva Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Warimpex Finanz- und Beteiligungs AG (WFS.DE) Income Statement Analysis – Financial Results
- Samhyun Co Ltd (437730.KQ) Income Statement Analysis – Financial Results
- Bank of the James Financial Group, Inc. (BOTJ) Income Statement Analysis – Financial Results
- Optimus Finance Limited (OPTIFIN.BO) Income Statement Analysis – Financial Results
- I G Petrochemicals Limited (IGPL.NS) Income Statement Analysis – Financial Results
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 724.74K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -724.74K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31,419.82B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| General & Administrative | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 39,503.64B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Income | 0.00 | 182.80K | 0.00 | 105.18K | 201.00 | 0.00 |
| Interest Expense | 0.00 | 182.80K | 2.41K | 1.45M | 469.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |
| EBITDA | -39,503.64B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39,503.64B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 39,503.60B | -11.91K | 1.59M | -1.35M | -469.17K | -557.68K |
| Income Before Tax | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Net Income | -39,260.84B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| EPS Diluted | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| Weighted Avg Shares Out | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
Source: https://incomestatements.info
Category: Stock Reports